MyBlueDots

DENVER–(BUSINESS WIRE)–Virta Health, the leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, announced record and accelerating growth of more than 60% year-over-year, at a scale of more than $100 million in annualized revenue. Driven by demand for its Sustainable Weight Loss (SWL) solution—now expanded to include ‘Responsible Prescribing’ capabilities—and continued growth of its diabetes reversal offering, Virta works with more than 550 organizations and c

PRINCETON, N.J. & TOKYO–(BUSINESS WIRE)–Otsuka America Pharmaceutical, Inc., (OAPI) and Otsuka Pharmaceutical, Co., Ltd. (Otsuka) announce that the U.S. Food and Drug Administration (FDA) plans to host a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting to seek input on issues related to the Supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD). The FDA’s decision to host a PDA

PALO ALTO, Calif.–(BUSINESS WIRE)–Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today announced it will collaborate with Merck as a premier platform to generate RWE, replicate studies and produce rapid insights and analytics on real-world data (RWD). Through this collaboration, Atropos Health will enable rapid cohort creation, advanced analytics and publication-grade studies in less than 48 hours. As part of the agreement

PALO ALTO, Calif.–(BUSINESS WIRE)– #GenAI–The partnership reflects both companies’ commitment to leveraging technology and human expertise to improve the last mile of healthcare delivery

MENLO PARK, Calif.–(BUSINESS WIRE)–Andreessen Horowitz (a16z) Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company (“Lilly”). The Biotech Ecosystem Venture Fund (“Fund”) seeks to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring new medicines and disease treatments to improve patients’ lives. M

SAN JOSE, Calif.–(BUSINESS WIRE)–VSee Health, Inc. (Nasdaq: VSEE), a leader in comprehensive digital health services and customized telehealth workflow streams, has been awarded a significant contract with a prominent, innovative health system in Florida valued at approximately $160,000. The contract value would grow significantly if deployment broadens. This partnership underscores VSee Health’s commitment to revolutionizing healthcare delivery through customized telehealth solutions that se

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD). The repeat dose study is a small exploratory U.S. Phase 2 multi-center, randomized, double-blind, place

NASHVILLE, Tenn.–(BUSINESS WIRE)–Nashville Biosciences LLC (NashBio), a leading real-world, multi-omics data company, today announced the launch of multiple next-generation, real-world data (RWD) solutions, including a research platform and therapeutic area collections over the next 6 months. These advancements will deliver unprecedented access to deidentified electronic health record (EHR) and linked genomic data, empowering life science researchers, pharmaceutical companies, and biotech inn